ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI’s Future Depends On Recruiting Youth to Careers in Science, NCI Director Says at His Swearing-In Ceremony.

October 20, 2006

Panel Says Tamoxifen Remains Standard for Preventing Breast Cancer

May 24, 2002

Kaiser Foundation Offers Community Health Grants

April 18, 1986

Funding opportunities listed.

October 8, 2004

Organ Systems R01 Grants Doing Okay

February 8, 1985

DCE Board Approves concept For New Studies On Black, White Differences In Cancer Rates

July 13, 1984